NasdaqGM:XENEBiotechs
Xenon Pharmaceuticals (XENE): Revenue Forecasts Soar 72.4% as Profitability Concerns Persist
Xenon Pharmaceuticals (XENE) reported continued unprofitability in its latest quarter and is projected to remain in the red for at least three more years. Over the past five years, losses have grown at an average yearly rate of 37%. However, revenue growth is forecast to accelerate at 72.4% per year, outpacing both the broader US market and the biotech sector. Despite substantial top-line momentum, margins and net profit have yet to improve, keeping earnings quality under pressure.
See our...